(S)-3-(1-Cyano-1,1-Diphenylmethyl)-1-Tosyloxypyrrolidine (Darifenacin)

In the commercial synthesis of darifenacin hydrobromide, the tosyloxy intermediate (S)-3-(1-cyano-1,1-diphenylmethyl)-1-tosyloxypyrrolidine functions as the electrophilic carrier of the chiral 3-(1-cyano-1,1-diphenylmethyl) motif. The convergent assembly of the API is executed in a jacketed stainless-steel reactor (typically 500–2,000 L glass-lined or Hastelloy C22) under an inert nitrogen blanket. The intermediate is dissolved in anhydrous tetrahydrofuran or 2-methyltetrahydrofuran at a concentration of 0.25–0.40 M and combined with 2-(2,3-dihydrobenzofuran-5-yl)ethylamine at a controlled molar ratio of 1.00:1.03 to 1.00:1.08. Anhydrous potassium carbonate or powdered sodium hydride (60 % dispersion in oil, 1.20–1.35 eq. relative to the intermediate) is charged portion-wise while maintaining an internal temperature of −5 °C to +5 °C through a recirculating chiller and brine-jacket system. Reaction mass pH is monitored via in-line attenuated total reflectance FTIR, targeting the disappearance of the sulfonate ester stretching band at 1,360 cm⁻¹ and 1,175 cm⁻¹. The alkylation is typically complete within 6–10 h. Post-reaction work-up involves quenching with pre-cooled 0.5 M ammonium chloride solution, phase separation, and washing of the organic layer with 10 % NaCl. The darifenacin free base is concentrated under reduced pressure (≤45 °C bath temperature to prevent retro-Michael elimination of the cyano group) and crystallized from isopropanol/n-heptane (1:3 v/v) to yield a white to off-white crystalline solid with chemical purity ≥99.3 % by HPLC at 230 nm and enantiomeric excess ≥99.7 %. The downstream process then converts the free base to the hydrobromide salt in acetone using 48 % aqueous HBr (1.02 eq.) to form darifenacin HBr, which is milled and classified to meet particle size distribution D₉₀ ≤50 µm for solid dosage uniformity. Regulatory compliance for this stage follows ICH Q7 GMP for Active Pharmaceutical Ingredients, Parts II and III, with emphasis on Section 8.3 (Sampling and Testing of Incoming Production Materials) and Section 19.2 (APIs for Use in Clinical Trials), together with ICH Q3A reporting thresholds for impurities set at 0.05 % or 0.10 % depending on the maximum daily dose. The terminal finished product arising from this vessel-based nucleophilic substitution is darifenacin hydrobromide EP/USP-grade API, subsequently formulated into extended-release tablets.

At what minimum residence time does microchannel flow achieve complete conversion while suppressing oxazoline by-products?

Continuous-flow process intensification using a 316L stainless-steel or silicon carbide microreactor (internal volume 1.0–10.0 mL, channel hydraulic diameter 0.5–1.0 mm) subjects the tosyloxy intermediate to precisely tuned thermal and stoichiometric windows difficult to replicate in batch mode. The intermediate stream (0.80 M in 2-MeTHF, pre-cooled to −10 °C) and the amine stream (0.82 M in 2-MeTHF containing 1.15 eq. of triethylamine) are fed by high-pressure piston pumps at a combined flow rate calibrated to deliver a molar ratio of 1.00:1.025 to 1.00:1.030. The reactant convergence occurs in an arrowhead mixer, and the resulting slug flow passes through a residence loop maintained at −2 °C ± 1 °C using a recirculating cryostat. At a residence time of 90–120 s, online Raman spectroscopy shows consumption of the tosylate group (C–O–S vibration, 815 cm⁻¹) exceeding 99.5 %, while the formation of the oxazoline side-product—arising from intramolecular cyclization when acyliminium species form—is held below 0.15 area-%. Pressure is controlled at 3.0 ± 0.2 bar via a back-pressure regulator to suppress outgassing of dissolved nitrogen. Short paths and rapid heat transfer coefficients (>800 W m⁻² K⁻¹) eliminate the 8–12 °C thermal gradients common in batch reactors, thereby preserving the (S)-configuration: chiral HPLC monitoring shows <0.2 % epimerization across a 48-hour campaign. Post-reaction, the stream is immediately quenched in-line with a 0.3 M citric acid solution; the organic phase is separated using a membrane-based liquid-liquid separator (PTFE, pore size 0.2 µm), dried in a packed column of molecular sieves 3 Å, and concentrated in a wiped-film evaporator at 40 °C jacket temperature and 50 mbar absolute pressure. Conformity with ICH Q13 (Continuous Manufacturing of Drug Substances and Drug Products) and the guidance on process analytical technology found in FDA PAT Guidance governs the control strategy, while equipment qualification follows ASTM E2500-20 (Standard Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment). The process generates darifenacin free base with ≥99.8 area-% purity that is then telescoped into salt formation. The final marketed dosage form is Enablex®-equivalent extended-release tablets containing 7.5 mg or 15 mg darifenacin.

Quality control laboratories supporting darifenacin API release rely on this intermediate as a high-purity working standard for chromatographic system suitability testing (SST) under USP General Chapter <621> and Ph. Eur. 2.2.46. A secondary standard stock solution is prepared by accurately weighing 10.0 mg of the tosyloxy reference material into a 50 mL Class A volumetric flask, dissolving with 25 mL of acetonitrile, sonicating for 10 min at 25 °C, and diluting to volume with water to yield a concentration of 0.20 mg/mL. This stock is further diluted to 0.002 mg/mL (1:100 v/v) in diluent composed of acetonitrile:water 40:60 v/v with 0.05 % trifluoroacetic acid for use as a sensitivity check solution. The laboratory injects 10 µL onto a 150 × 4.6 mm C18 column (3.5 µm particle size) maintained at 35 °C with UV detection at 230 nm and a flow rate of 1.2 mL/min. The gradient starts at 30 % mobile phase B (acetonitrile) and ramps to 90 % over 25 min with a total run time of 35 min. System suitability criteria mandated by the pharmacopoeial monograph require the resolution between the intermediate peak and darifenacin to be not less than 2.0, and the tailing factor (T_f) for the intermediate peak not to exceed 1.5 calculated at 5 % peak height. The percent relative standard deviation for five replicate injections of the 0.002 mg/mL solution must be ≤5.0 %. The downstream production process in this context is the analytical quality control workflow, and the terminal output is a valid certificate of analysis (CoA) enabling batch disposition decisions for darifenacin API destined for tablet compression. The entire procedure is embedded within the site’s ICH Q2(R1) validation master plan and is audited against ISO/IEC 17025:2017 general requirements for testing competence.

Chiral Discrimination Limits in R-Enantiomer Spiking Studies

The tosyloxy intermediate presents a specific risk for enantiomeric carry-through because the stereocenter at the pyrrolidine 3-position is susceptible to base-catalyzed proton exchange under the biphasic conditions used in the final coupling. Darifenacin monographs (USP, Ph. Eur.) limit the (R)-enantiomer impurity to ≤0.10 %. Conformance testing employs an (R)-enantiomer reference standard—derived by stereoselective synthesis or chiral preparative chromatography—spiked into a test mixture of the intermediate at a verified addition level of 0.10 % (w/w). A precisely weighed 25.0 mg portion of darifenacin resolution mixture, obtained by spiking the intermediate with the (R)-standard, is dissolved in 5.0 mL of mobile phase consisting of n-hexane:ethanol:diethylamine 90:10:0.1 v/v. Chromatographic separation is achieved on a 250 × 4.6 mm Chiralpak AD-H analytical column (5 µm) operated isocratically at 1.0 mL/min and 25 °C. Detection at 210 nm exhibits a limit of quantitation (LOQ) for the (R)-enantiomer of 0.02 % relative to the darifenacin peak. Multiple batch records document that when the coupling reaction mixture exceeds +8 °C for more than 45 min during phase separation, (R)-isomer levels rise to 0.12 %–0.18 %, causing batch failure. The downstream quality control process therefore includes mandatory cooling hold-times verified by temperature loggers compliant with 21 CFR Part 11. The terminal product of this analytical investigation is a darifenacin hydrobromide API batch with certificate of analysis stating enantiomeric purity, released in conformance with ICH Q6A Decision Tree #4 (Chiral Assay Considerations) and the specific impurity clauses of the relevant pharmacopoeial individual monograph. Pharmacokinetic bridging studies (referenced in clinical dossiers per ICH M4Q CTD) rely on the absence of quantifiable (R)-enantiomer above the threshold.

When the tosyloxy intermediate is subjected to forced oxidative degradation at pH extremes for stability-indicating method development

Stress testing protocols prescribed by ICH Q1A(R2) and Q1B for darifenacin hydrobromide incorporate the intermediate as a surrogate substrate to model the intrinsic oxidative lability of the cyano-diphenylmethyl moiety without the confounding effects of the dihydrobenzofuran ring. In a typical forced degradation experiment, 10.0 mg of the intermediate is dissolved in 10 mL of acetonitrile and treated with 1.0 mL of 3 % (v/v) hydrogen peroxide solution, representing a molar ratio of intermediate to H₂O₂ of approximately 1:12. The mixture is held at 60 °C ± 2 °C in a thermostatted water bath for 24 h under exclusion of light. Aliquots are withdrawn at 0, 1, 3, 6, and 24 h, neutralized with catalase solution, and analyzed by RP-UHPLC coupled with high-resolution quadrupole-time-of-flight mass spectrometry (QTOF, resolution >30,000 FWHM). Degradation at the cyano group yields the corresponding amide (MH+ + 18 Da) and carboxylic acid (MH+ + 19 Da), while radical oxidation at the benzhydryl methine carbon produces benzophenone through C–C bond scission. The resolved degradation products are isolated via semi-preparative HPLC on a 10 × 250 mm C18 column (5 µm) with peak-triggered fraction collection, then lyophilized. These characterized isolates serve as impurity reference markers in the API stability-indicating method, spiked into darifenacin assay preparations at the reporting threshold of 0.05 %. Compliance with ICH Q3B qualification thresholds is demonstrated by showing that no unknown impurity exceeds 0.15 %. The terminal process output is a validated impurity profiling method registered in the Type II DMF, enabling shelf-life assignments and packaging recommendations (e.g., Alu-Alu blister under nitrogen). The finished dosage form remains extended-release tablets with defined photostability and oxidative stability labeling statements.

Multi-kilogram contract manufacturing campaigns for the tosyloxy intermediate demand rigorous incoming material controls because subtle variations in residual water and solvent composition can shift the stoichiometry of the subsequent N-alkylation by more than 3 %. Producer certificates citing Karl Fischer moisture values between 0.08 % and 0.35 % have correlated directly with a 4.2 % absolute reduction in coupling yield when moisture exceeds 0.25 %, due to competing hydrolysis of the anhydrous base. Consequently, all intermediate batches are unconditionally re-dried in a conical vacuum dryer (45 °C, ≤10 mbar, double-cone rotation 6 rpm) for 24 h under a nitrogen sweep of 0.5 L/min until Karl Fischer analysis confirms moisture ≤0.10 %. The dried intermediate is immediately packaged under positive nitrogen pressure into double polyethylene liners inside a sealed aluminium laminate bag containing a desiccant pouch (silica gel, 25 g/1 kg intermediate). Short-term storage at −20 °C ± 5 °C and long-term at −40 °C ± 5 °C is validated per ICH Q1A(R2) condition for frozen storage. The downstream manufacturing process for the API utilizes the dried intermediate in a one-pot sequence: dissolution in anhydrous dimethylformamide (5 volumes), coupling with the amine at 0 °C, and extractive work-up. The terminal finished product is the darifenacin hydrobromide API meeting EP 10.0/USP 43 specifications. Supplementary compliance is maintained with ICH Q9 (Quality Risk Management) applied to the drying–moisture failure mode and with EU GMP Part I Chapter 5 on production vendor qualification. The table below summarizes residual solvent specifications applied to the intermediate before release for the coupling step, aligning with ICH Q3C (R8) maintenance of permitted daily exposures.

*2-MeTHF is regulated as a Class 3 solvent in accordance with ICH Q3C Table 3; the 50 mg/day PDE corresponds to a 0.5 % w/w option 2 concentration limit.

An additional analytical control scenario in stability-chamber monitoring programs employs the tosyloxy intermediate as a process-related impurity spike in placebo blend uniformity studies. Granulation blends for extended-release tablets are spiked with the intermediate at a level corresponding to 0.10 % of the label claim (7.5 µg/tablet for the 7.5 mg dosage) to verify that the extraction procedure and gradient elution can resolve the tosyloxy signal from darifenacin and formulation excipients such as hypromellose and magnesium stearate. The extraction uses 20 mL of 0.1 M HCl:acetonitrile 60:40 v/v per 5 tablets subjected to orbital shaking at 200 rpm for 45 min. After centrifugation (4,000 rpm, 10 min), the supernatant is passed through a 0.45 µm PTFE syringe filter and analyzed using the same HPLC conditions described for API assay. The detectable limit ensures that any carry-over of unreacted intermediate into the final drug product can be controlled well below the 1.5 µg/day ICH Q3B qualification threshold. The terminal finished product remains the marketed extended-release tablet, and the compliance framework draws together USP General Chapter <1225> (Validation of Compendial Procedures) and 21 CFR 211.165(e) for test method accuracy. No conclusion follows; the scenario-specific technical content terminates here.